Telomir Pharmaceuticals, Inc. Common Stock
TELO · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $43,146 | $37,513 | $96,133 | $121,702 |
| - Cash | $7,329 | $754 | $403 | $1,266 |
| + Debt | $0 | $93 | $93 | $93 |
| Enterprise Value | $35,816 | $36,852 | $95,824 | $120,529 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$1,100 | -$5,069 | -$2,180 | -$2,898 |
| % Margin | – | – | – | – |
| Net Income | -$1,102 | -$5,070 | -$2,180 | -$2,898 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.034 | -0.17 | -0.073 | -0.098 |
| % Growth | 80% | -132.2% | 25.3% | – |
| Operating Cash Flow | -$927 | -$696 | -$863 | -$606 |
| Capital Expenditures | $0 | $0 | $0 | -$0 |
| Free Cash Flow | -$927 | -$696 | -$863 | -$606 |